Correction to: Biomarker-driven population enrichment for adaptive oncology trials with time to event endpoints (Statistics in Medicine (2014) 33, (4515-4531), 10.1002/sim.6272);Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints

Statistics in Medicine

Volumn 33, Issue 26, 2014, Pages 4515-4531

  Mehta, Cyrus ^a   Schäfer, Helmut ^b   Daniel, Hanna ^c   Irle, Sebastian ^d  

^a Cytel Software Corporation   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d German Central Bank   (Germany)

Author keywords

Adaptive design; Clinical trial; Conditional error function; Multiple comparisons; Precision medicine; Predictive biomarker; Subgroup selection; Survival endpoints; Targeted therapies

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANALYTICAL ERROR; ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; EXPERIMENTAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; METHODOLOGY; ONCOLOGY; POPULATION RESEARCH; RESEARCH SUBJECT; SIMULATION; STATISTICAL ANALYSIS; BIOASSAY; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; GENETICS; HUMAN; LUNG NEOPLASMS; PATIENT SELECTION; PROCEDURES; SURVIVAL;

BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 84907890908     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.7068     Document Type: Erratum

References (18)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews (Drug Discovery) 2004; 3: 711-715.
2. Toll J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clinical Therapeutics 2010; 32(3):437-453.
3. Bauer P, Posch M. Letter to the editor. Statistics in Medicine 2004; 23:1333-1335.
4. Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 2009; 28:1445-1463.
5. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10:347-356.
6. Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 2012; 31(30):4309-4320.
7. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analysis. Biometrics 1994; 50:1029-1041.
8. Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:2497-2508.
9. Spiessens B, Debois M. Adjusted significance levels for subgroup analysis in clinical trials. Contemporary Clinical Trials 2011; 31:647-656.
10. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, De Gramont A. Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 2011; 2(11):171-182.
11. Marcus R, Peritz E, Gabriel K. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1974; 63:655-660.
12. Irle S, Schäfer H. Interim design modifications in time-to-event studies. Journal of the American Statistical Association 2012; 107:341-348.
13. Magirr D, Jaki T, Koenig F, Posch M. Adaptive survival trials. Stat. AP 2014. arXiv: 1405.1569v1.
14. Gollerkeri A. Personal communication from Ashwin Gollerkeri, M.D. Executive Director: Cambridge, Massachusetts, 2013.
15. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clinical Cancer Research 2007; 13(15 Suppl):2007.
16. Inoue LT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002; 58:823-831.
17. Thall PF, Nguyen HQ, Wang X, Wolff JE. A hybrid geometric phase II-III clinical trial design based on treatment failure time and toxicity. Journal of Statistical Planning and Inference 2012; 142:944-955.
18. Di Scala L, Glimm E. Time-to-event analysis with treatment arm selection at interim. Statistics in Medicine 2011; 30:3067-3081.